EVANOVO®, the vaccine that will revolutionize
the prevention of avian coccidiosis The first and only vaccine against coccidiosis in chickens attenuated by precociousness that has been developed for administration in ovo.
Avian coccidiosis is one of the main destabilizing agents of the digestive health of birds. Besides, in- ovo vaccination is attracting the interest from poultry producers as a method of administration of vaccines, as it makes the process individual, precise and cheaper. Due to it, HIPRA decided to research in in-ovo vaccination against avian coccidiosis and is now launching EVANOVO® on to the world market.
EVANOVO®, main characteristics
Among the main characteristics of EVANOVO®, it includes only strains of Eimeria spp. highly attenuated through precociousness. It contains the strains of the main species that affect broilers: Eimeria acervulina, E. maxima, E. praecox and E. tenella. Another feature of EVANOVO® is its sterilization process, through which any contamination is avoided, and no antimicrobial substances are needed to be included. And the immunity acquired is extended to a minimum of 63 days post-vaccination.
Moreover, EVANOVO® can be applied in the same injection with other vaccines such as GUMBOHATCH®, HIPRA’s immunocomplex vaccine against IBDV. This combination has been shown not to affect the stability or efficacy of any of the co-administered vaccines.
Administration, key to ensuring the success of the process
As it is a vaccine that contains live Eimeria oocysts, and due to its mechanism of action, EVANOVO® should be applied into the amniotic cavity. If this is successful, the embryo will consume the vaccine solution orally and, at hatching, the replication process of the vaccine strains will begin in the chick’s intestine. To achieve this goal, HIPRA has developed the GLOBAL HATCHERY HEALTH PROGRAMME. One of its objectives is based on auditing the Site of Injection (SOI) of the embryonated eggs before they are vaccinated.
Vaccination experiences with EVANOVO®
Finally, the results obtained in different vaccination experiences on farms in Belgium and Spain show that protection against coccidiosis through a method as novel as in-ovo injection, using HIPRA’s new vaccine, EVANOVO®, is just as effective as that obtained aſter vaccination using more traditional methods.
In none of the parameters evaluated (Hatching rate, mortality, Feed Conversion Ratio, Body Weight Gain, Coccidiosis Lesion Score or OPG Counting) was there a statistically significant difference between EVANT®, a widely adopted vaccine with demonstrated results & EVANOVO®. For more information, please get in touch with
hipra@hipra.com.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
